(Q35131235)

6 August 2017

1 reference

title

Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells (English)

1 reference

6 August 2017

Wakimoto H

1

1 reference

6 August 2017

Johnson PR

series ordinal

2

1 reference

6 August 2017

Knipe DM

series ordinal

3

1 reference

6 August 2017

Chiocca EA

series ordinal

4

1 reference

6 August 2017

publication date

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

10

1 reference

6 August 2017

issue

11

1 reference

6 August 2017

page(s)

983-990

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302038

6 August 2017

exact match

0 references

cites work

Oncolytic viruses as novel anticancer agents: turning one scourge against another

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Linkages of innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Humoral response to herpes simplex virus is complement-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

The nature of the principal type 1 interferon-producing cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Natural interferon alpha/beta-producing cells link innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Herpes simplex virus selectively induces expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on PKR and ICP0

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Immunoglobulin binding to herpes virus-induced Fc receptors inhibits virus growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Herpes simplex virus turns off the TAP to evade host immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

The role of the UL41 gene of herpes simplex virus type 1 in evasion of non-specific host defence mechanisms during primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Complement and innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Quantitation of HSV mass distribution in a rodent brain tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

The complement response against an oncolytic virus is species-specific in its activation pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Human serum lyses RNA tumour viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Complement and anti-alpha-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not in umbilical cord serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Specific recognition of protein carboxy-terminal sequences by natural IgM antibodies in normal serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Broad expression of Toll-like receptors in the human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Complement activation in the central nervous system following blood-brain barrier damage in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Butyrate-induced reversal of herpes simplex virus restriction in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Central Role of Double-Stranded RNA-Activated Protein Kinase in Microbial Induction of Nitric Oxide Synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

Interleukin-18 protects mice against acute herpes simplex virus type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Isolation and characterization of a mannan-binding protein from human serum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Purification and characterization of two mannan-binding lectins from mouse serum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Mapping the in vivo distribution of herpes simplex virions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and janus kinases during an early infection stage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

RNA expression of complement regulatory proteins in human brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Nitric oxide and macrophage antiviral extrinsic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302038

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302038

1 reference

6 August 2017

1 reference